Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs S&P500 ETF (SPY) Price & Performance

ResMed Inc.Trade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs S&P500 ETF — how do they compare? ResMed Inc. trades at $226.34 (market cap $32.61B), while S&P500 ETF trades at $773.14. The key difference: ResMed Inc. pays a 1.17% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.

RMDSPY
Market Cap
$32.61B
Sector
Health
52-Week High
$293.73$773.22
52-Week Low
$182.82$631.99
Enterprise Value
$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

S&P500 ETF

SPY, the SPDR S&P 500 ETF Trust, trades at $772.90 with minimal daily movement (-0.02%). Technical indicators show a bullish trend with moving averages supporting upside momentum, though oscillators signal potential overbought conditions. The ETF maintains its position as the world's largest fund with approximately $676 billion in assets. Recent news highlights the S&P 500 reaching record highs while facing valuation concerns with the Shiller P/E ratio at 42, the highest since the dot-com era.

The ETF's outlook remains positive with institutional targets pointing toward 8,000 levels, though elevated valuations and weak market breadth present near-term risks. Dividend income continues to attract investors with reliable distributions, but fee comparisons with competing funds highlight cost considerations for long-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY